PTD-DBM.
PTD-DBM is a synthetic, cell-permeable peptide whose name stands for "Protein Transduction Domain–Dishevelled Binding Motif." It fuses a short protein-transduction (cell-penetrating) domain to a peptide sequence that mimics the Dishevelled-binding region of the protein CXXC5, allowing it to act as a competitive decoy.
PTD-DBM is a synthetic, cell-permeable peptide whose name stands for "Protein Transduction Domain–Dishevelled Binding Motif." It fuses a short protein-transduction (cell-penetrating) domain to a peptide sequence that mimics the Dishevelled-binding region of the protein CXXC5, allowing it to act as a competitive decoy. PTD-DBM is research / preclinical, and PepCue grades its published evidence F tier (12/100). This is a research reference, not medical or dosing advice.
What it is
PTD-DBM is a synthetic, cell-permeable peptide whose name stands for "Protein Transduction Domain–Dishevelled Binding Motif." It fuses a short protein-transduction (cell-penetrating) domain to a peptide sequence that mimics the Dishevelled-binding region of the protein CXXC5, allowing it to act as a competitive decoy. It was created as a research tool to manipulate Wnt/β-catenin signaling in skin and hair-follicle biology and is not a drug, nutritional product, or approved therapeutic.
How it works
CXXC-type zinc finger protein 5 (CXXC5) is a negative-feedback regulator of canonical Wnt/β-catenin signaling that works by binding the scaffolding protein Dishevelled (Dvl), preventing Dvl from transmitting the Wnt signal. PTD-DBM carries a sequence that imitates the Dvl-binding motif, so it competitively occupies that interface and disrupts the CXXC5–Dvl interaction. Freed from CXXC5 inhibition, Dvl can stabilize β-catenin, which in turn drives transcriptional programs associated with the anagen (growth) phase of the hair cycle, dermal-papilla activity, and epithelial proliferation in wounds. In the founding work this de-repression of Wnt signaling was the proposed basis for both accelerated hair regrowth and wound-induced hair neogenesis (de novo follicle formation within healing skin).
Mechanism pathways
Releasing a brake on the pathway that drives hair-follicle cycling and epithelial regeneration.
The canonical Wnt pathway is one of the core developmental signalling systems, conserved across animals and central to tissue regeneration. In its resting state a destruction complex containing APC, axin, and GSK-3 beta continuously phosphorylates beta-catenin and marks it for degradation, so beta-catenin never accumulates. When a Wnt ligand binds Frizzled and its LRP co-receptor, the scaffolding protein Dishevelled is recruited and inhibits that destruction complex. Beta-catenin then accumulates, enters the nucleus, and partners with TCF and LEF transcription factors to switch on programmes of proliferation and differentiation. In skin, this pathway governs the hair cycle. Wnt and beta-catenin activity in dermal papilla cells and follicular epithelium is what drives the transition from the resting telogen phase into the growing anagen phase, and it is likewise involved in re-epithelialisation after wounding. Because the pathway is so powerful it is heavily restrained by negative regulators, and one of these is a zinc-finger protein that binds Dishevelled and prevents it from transmitting the Wnt signal. The compound here is a peptide carrying a sequence that imitates the Dishevelled-binding motif of that negative regulator. By competitively occupying the same interface, it displaces the inhibitor from Dishevelled. Freed from that restraint, Dishevelled can stabilise beta-catenin, and the downstream transcriptional programme proceeds. This is de-repression rather than stimulation, an important distinction: the compound does not add Wnt signal, it removes a brake on signal that is already present, which in principle keeps the response tied to existing physiological cues. A protein transduction domain is included to help the peptide reach its intracellular target, since the interface it needs to disrupt is inside the cell. The honest counterweight to all of this is oncology. Constitutive activation of Wnt and beta-catenin signalling, usually through APC mutation, is the defining early event in the great majority of colorectal cancers, and the pathway is implicated in several other malignancies. Any intervention that raises beta-catenin activity therefore carries an inherent theoretical concern that has not been characterised in humans for this compound. The founding work was preclinical, conducted in mouse models of hair growth and wound healing. There are no controlled human trials, the compound is not approved anywhere, and material sold under this name is unregulated.
The evidence
The evidence base is preclinical. The foundational study (Lee et al., J Invest Dermatol 2017, PMID 28595998) reported that CXXC5 is elevated in balding human scalp and that disrupting the CXXC5–Dishevelled interaction with the competing peptide activated Wnt/β-catenin signaling, accelerated hair regrowth, and promoted wound-induced hair neogenesis in mice; effects were enhanced when combined with valproic acid (a GSK3β-modulating Wnt activator), and Cxxc5-knockout mice phenocopied the benefit. Earlier work established CXXC5 itself as a negative regulator of cutaneous wound healing (Lee et al., J Exp Med 2015, PMID 26056233), and a 2023 study (Cells, PMID 36831222) linked CXXC5 to DHT/PGD2-driven androgenetic alopecia, supporting the target's relevance. The same Yonsei group later advanced a small-molecule Wnt activator, KY19382 (Br J Pharmacol 2021, PMID 33751552), as a more drug-like successor. Critically, no human clinical trials of PTD-DBM have been published; human relevance rests on cultured human follicle cells and on the observation of elevated CXXC5 in bald scalp, not on controlled efficacy data in people.
The evidence, in brief
A cell-penetrating peptide that activates Wnt/β-catenin signalling (disrupting CXXC5–Dishevelled), with reported hair-regrowth effects in mouse models. Evidence is animal/lab only, with no completed human efficacy trials. Investigational, not an approved hair-loss treatment.
- Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesisJ Invest Dermatol, 2017 (PMID 28595998)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #053
Little indexed evidence or largely speculative.
Mostly online reports, no real study base yet.
Claim receipts
Popular claims about PTD-DBM, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Regrowth findings come from mouse work and cultured human follicle cells; no human trial has been published.
Wound-induced follicle neogenesis was reported in mice, and that outcome has not been shown in people.
There is no registered clinical program for the peptide itself, so no comparison with approved treatments is possible.
No human safety, pharmacokinetic or toxicology data exist, and broadly de-repressing Wnt signaling raises unstudied proliferation questions.
Safety profile
There are no published human safety data, pharmacokinetics, or toxicology studies for PTD-DBM; it has been used only as an experimental reagent in animal and cell-culture models, so its safety profile in humans is genuinely unknown. As a cell-penetrating peptide that broadly de-represses Wnt/β-catenin signaling, a theoretical concern is that sustained or systemic Wnt activation could have off-target effects on tissues where the pathway influences proliferation, though no such outcomes have been characterized for this peptide specifically. Material sold online is research-use-only, is not produced or tested to pharmaceutical quality standards, and purity, sterility, and identity cannot be assumed. Anyone encountering PTD-DBM should treat it strictly as an unapproved experimental compound.
Compound notes
- PTD-DBM is a peptide that disrupts the CXXC5–Dishevelled interaction, thereby activating Wnt/β-catenin signaling.
- It is studied for hair regrowth, typically topical and in combination with valproic acid, in animal models.
- Not FDA-approved; research-only.
- Human hair-regrowth evidence is minimal.
Regulatory status
PTD-DBM is an investigational research compound; it is not approved by the FDA or any major regulator for any indication, and it is not in marketed dermatologic products. It is not a WADA-listed substance, and the published work remains preclinical with no registered human clinical program for the peptide itself.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Name expands to Protein Transduction Domain–Dishevelled Binding Motif; the PTD portion makes the peptide cell-permeable
- 02Acts as a competitive decoy that blocks the CXXC5–Dishevelled interaction, de-repressing Wnt/β-catenin signaling
- 03First reported by Kang-Yell Choi's group at Yonsei University in the Journal of Investigative Dermatology (2017)
- 04Studied for hair regrowth and wound-induced hair neogenesis (new follicle formation in healing skin) in mice
- 05Frequently paired with valproic acid in studies, which activates Wnt through a separate GSK3β-related mechanism
- 06No human clinical trials published; all efficacy evidence is from rodent models and cultured cells
PTD-DBM: research formats
Choose the format you are researching to see route-specific notes.
Applied to skin in rodent hair-regrowth experiments. No human trials and no human format.
PTD-DBM is a cell-permeable research peptide built to block the CXXC5 and Dishevelled interaction and de-repress Wnt signaling in skin. Its protein-transduction domain is what lets it cross cell membranes, and the published work applies it to the skin of mice to study hair regrowth and wound-induced hair neogenesis. All efficacy evidence is from rodent models and cultured cells, so no human administration format exists.
In the published studies it is frequently paired with valproic acid, which activates Wnt through a separate GSK3-beta-related mechanism. Results from the pair do not describe what the peptide does alone.
PTD-DBM is a research tool rather than a drug. It is not approved by any regulator, appears in no marketed dermatologic product, and has no registered human clinical program.
Sources
Every factual claim above resolves to a real, published source.
- Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair NeogenesisJournal of Investigative Dermatology, 2017, 137(11):2260-2269, PMID 28595998
- The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healingJournal of Experimental Medicine, 2015, PMID 26056233
- CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2Cells, 2023, 12(4):555, PMID 36831222
- KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesisBritish Journal of Pharmacology, 2021, 178(12):2533-2546, PMID 33751552
Cite this page
PepCue. “PTD-DBM: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/ptd-dbm.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.